Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

被引：0
|
作者：
Sizheng Zhao
Laura Chadwick
Eduardo Mysler
Robert J. Moots
机构：
[1] University of Liverpool,Department of Musculoskeletal Biology I, Clinical Sciences Centre, Institute of Ageing and Chronic Disease
[2] Aintree University Hospital,undefined
[3] Organización Medica de Investigación,undefined
来源：
Current Rheumatology Reports | 2018年 / 20卷
关键词：
Adalimumab; Biosimilar; Rheumatoid arthritis; Amgevita; Cyltezo; Imraldi;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Adalimumab in the treatment of rheumatoid arthritis
    Voulgari, Paraskevi V.
    Kaltsonoudis, Evripidis
    Papagoras, Charalampos
    Drosos, Alexandros A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (12) : 1679 - 1686
  • [22] Adalimumab - A review of its use in adult patients with rheumatoid arthritis
    Cvetkovic, Risto S.
    Scott, Lesley J.
    BIODRUGS, 2006, 20 (05) : 293 - 311
  • [23] Adalimumab for the treatment of rheumatoid arthritis
    Miyasaka, Nobuyuki
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (01) : 19 - 26
  • [24] Adalimumab in rheumatoid arthritis.
    Moreland L.
    Current Rheumatology Reports, 2004, 6 (5) : 333 - 334
  • [25] Adalimumab for treating rheumatoid arthritis
    Navarro-Sarabia, Federico
    Ariza-Ariza, Rafael
    Hernandez-Cruz, Blanca
    Villanueva, Isidro
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (06) : 1075 - 1081
  • [26] Adalimumab in the treatment of rheumatoid arthritis
    Voulgari, Paraskevi V.
    Drosos, Alexandros A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (04) : 549 - 561
  • [27] Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity
    Kang, Jia
    Eudy-Byrne, Rena J.
    Mondick, John
    Knebel, William
    Jayadeva, Girish
    Liesenfeld, Karl-Heinz
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (11) : 2274 - 2285
  • [28] Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
    Christopher J. Edwards
    Joëlle Monnet
    Martin Ullmann
    Pantelis Vlachos
    Veranika Chyrok
    Vishal Ghori
    Clinical Rheumatology, 2019, 38 : 3381 - 3390
  • [29] Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis
    Edwards, Christopher J.
    Monnet, Joelle
    Ullmann, Martin
    Vlachos, Pantelis
    Chyrok, Veranika
    Ghori, Vishal
    CLINICAL RHEUMATOLOGY, 2019, 38 (12) : 3381 - 3390
  • [30] Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
    Huizinga, Tom W. J.
    Torii, Yoshifumi
    Muniz, Rafael
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 41 - 61
12345